Inhibition of tumor cell growth by a human B-cell line

An Adenocarcinoma cell line (Breast-M) and an Epstein-Barr virus (EBV)-infected B-cell line (Hairy-BM) were established from breast tumor tissue. The Hairy-BM was CD20+, CD25 (Tac)+ and surface immunoglobulin (sIg)+. Hairy-BM suppressed the in vitro proliferation of Breast-M in a time and a dose-dependent manner. The suppression was also found in 5 different human tumor targets showing tumor-Hairy-BM binding, but not; in 2 murine tumor targets showing no significant tumor-Hairy-BM binding. Lytic activity of Hairy-BM was found only against Breast-M.

[1]  Tomohiro Hayashi,et al.  The Mechanisms of Cytotoxicity to Tumor Cells by Polymorphonuclear Leukocytes Stimulated with Cytokines , 1988, Japanese journal of cancer research : Gann.

[2]  W. Greene,et al.  Direct demonstration of the identity of T cell growth factor binding protein and the Tac antigen , 1983, The Journal of experimental medicine.

[3]  B. Mitchell,et al.  CD11c (LEU-M5) expression characterizes a B-cell chronic lymphoproliferative disorder with features of both chronic lymphocytic leukemia and hairy cell leukemia. , 1990, Blood.

[4]  G. Klimpel,et al.  Lymphotoxin and interferon production by rossette-separated human peripheral blood leukocytes. , 1976, Cellular immunology.

[5]  J. Roth,et al.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells , 1983, The Journal of experimental medicine.

[6]  T. Waldmann,et al.  Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells , 1984, Nature.

[7]  M. Caligiuri,et al.  Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. , 1990, Journal of immunology.

[8]  L. Old,et al.  Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Waldmann,et al.  Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[10]  S. Rosenberg,et al.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. , 1984, Cancer research.

[11]  N. Damle,et al.  Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. , 1986, Journal of immunology.

[12]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[13]  P. Lipsky,et al.  The roles of interleukin 2 and interferon‐γ in human B cell activation, growth and differentiation , 1986, European journal of immunology.

[14]  H. Müller-Eberhard,et al.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO , 1965, The Journal of experimental medicine.

[15]  K. Holmes,et al.  Natural cytotoxicity against mouse hepatitis virus-infected cells. II. A cytotoxic effector cell with a B lymphocyte phenotype. , 1986, Journal of immunology.

[16]  D. Hafeman,et al.  Polymorphonuclear leukocyte-mediated, antibody-dependent, cellular cytotoxicity against tumor cells: dependence on oxygen and the respiratory burst. , 1979, Journal of immunology.

[17]  P Hogeweg,et al.  Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.

[18]  A. Lichtenstein,et al.  Anti‐tumor effect of inelammatory neutrophils: Characteristics of in vivo generation and in vitro tumor cell lysis , 1985, International journal of cancer.

[19]  R. Mertelsmann,et al.  Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. , 1983, Journal of immunology.

[20]  B. Stadler,et al.  Interleukin 2 dependence of human natural killer (NK) cell activity. , 1983, Journal of immunology.

[21]  S. Rosenberg,et al.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. , 1986, Science.

[22]  T. Hirano,et al.  Effect of recombinant IL 2 and gamma-IFN on proliferation and differentiation of human B cells. , 1985, Journal of immunology.

[23]  A. Fauci,et al.  Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function , 1985, The Journal of experimental medicine.

[24]  M. Tsudo,et al.  Expression of Tac antigen on activated normal human B cells , 1984, The Journal of experimental medicine.

[25]  R. Herberman,et al.  Natural killer cells. , 1986, Annual review of medicine.

[26]  Kendall A. Smith,et al.  Long term culture of tumour-specific cytotoxic T cells , 1977, Nature.